Pharmaceutical formulations of immune checkpoint inhibitors

The present invention relates to pharmaceutical formulations of antibodies and antigen binding fragments directed against human programmed death receptor-1 (PD-1)/programmed death receptor ligand 1 (PD-L1), and methods for preparing the pharmaceutical formulations. The disclosed formulations are free of chelating agents and stabilize anti-PD1/anti-PDL1 antibodies from lower to higher concentrations, thereby making them suitable for different modes of administration (subcutaneous/intravenous). 本发明涉及针对人程序性死亡受体-1(PD-1)/程序性死亡受体配体1(PD-Ll)的抗体和抗原结合片段的药物配制物，以及用于制备所述药物配制物的方法。所公开的配制物不含螯合剂，并且使从较低浓度到较高浓度的抗PD1/抗PD L1抗体稳定，从而使其适合于不同的施用模式(皮下/静脉内)。